Abstract | PURPOSE: METHODS: RESULTS: During 5 days after chemotherapy, 64% of patients receiving the aprepitant regimen and 47% of those receiving the UK comparator regimen had a complete response to antiemetic therapy (no emesis and no rescue antiemetic therapy). A mean of £37.11 (78%) of the cost of aprepitant was offset by reduced health care resource utilization costs. The predicted gain in quality-adjusted lifeyears (QALYs) with the aprepitant regimen was 0.0048. The incremental cost effectiveness ratio (ICER) with aprepitant, relative to the UK comparator, was £10,847/QALY, which is well below the threshold commonly accepted in the UK of £20,000-£30,000/QALY. CONCLUSION: The results of this study suggest that aprepitant is cost-effective for preventing CINV associated with chemotherapy for patients with breast cancer in the UK health care setting.
|
Authors | Samantha Humphreys, James Pellissier, Alison Jones |
Journal | Cancer management and research
(Cancer Manag Res)
Vol. 5
Pg. 215-24
( 2013)
ISSN: 1179-1322 [Print] New Zealand |
PMID | 23950658
(Publication Type: Journal Article)
|